Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

VALPAS

Financiado

Cerrado

VALidation of human PApilloma virus assays on Self collected first void urine sa...

VALidation of human PApilloma virus assays on Self collected first void urine samples Annually, about 13,000 women in the EU28 and 266,000 worldwide decease of cervical cancer caused by the human papilloma virus (HPV), thereby ranking third most common cancer worldwide . Throughout Europe, cervical screening progra... ver más

31/10/2015

Novosanis

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

NOVOSANIS NV No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2015-10-31

PHC-12-2015-1: Clinical research for the validatio...

I+D

Cerrada hace 9 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

Novosanis

50.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

MIMICS MicroRNA Isoforms for Molecular Interception of Cervical can... 150K€ Cerrado

CHILI A Community based HPV screening implementation in Low Income... 3M€ Cerrado

SELFPOCNAD SelfPOCNAD Development of a Point of Care Detection Device... 2M€ Cerrado

HoloCyt A rapid low cost cervical cancer screening platform 71K€ Cerrado

HPV OncoPredict A Groundbreaking Stand Alone Diagnostic Kit to Predict Human... 3M€ Cerrado

VALID-SCREEN Validation of PreCursor M for enhanced Cervical Pre Cancer... 3M€ Cerrado

Duración del proyecto: 1 meses Fecha Inicio: 2015-09-15
Fecha Fin: 2015-10-31

Líder del proyecto

NOVOSANIS NV No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Annually, about 13,000 women in the EU28 and 266,000 worldwide decease of cervical cancer caused by the human papilloma virus (HPV), thereby ranking third most common cancer worldwide . Throughout Europe, cervical screening programs are organized by local governments to detect cervical cancer at an early stage. Importantly, HPV-based screening (instead of cytology-based screening) is being implemented worldwide. However, a global challenge is that about 40% of women in the EU do not participate in these screening programs and are thus at-risk for development of cervical cancer. To reach these non-attendees, home self-sampling devices can increase the participation rate. The innovative Colli-PeeTM device developed by Novosanis offers a non-invasive, user-friendly solution. The device is suited for collection of first void urine (first 20ml of the urine flow) which allows for detection of HPV DNA. The Colli-PeeTM device thereby offers a novel innovative approach towards HPV-based screening. The VALPAS (VALidation of human PApilloma virus assays on Self-collected first void urine samples) project aims to successfully launch the Colli-Pee first void urine collection for HPV DNA testing in the EU28 and global market. The feasibility assessment in phase I aims to explore strategies with regard to market penetration & growth, competitors, pricing & reimbursement, partnerships, revenue models; ultimately leading to a business plan for Colli-PeeTM-based HPV screening. Specifically, phase I entails: - Market segment analysis - Competitor bench marking - Initiation of partnerships with diagnostic companies & labs - Exploration of pricing & reimbursement strategy - Assessment of diagnostic assays for analysis for HPV in urine Phase II funding will be requested to further validate the HPV assays for detection of HPV DNA in first void urine and set-up full scale production and exploitation strategy in the EU28 and at global level.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores